IP Library Granted Patent US 9,884,820
Granted Patent B2
US 9,884,820 · App. 15/250,117 · Granted Feb 6, 2018

Pro-neurogenic compounds

Inventors: Steven L. McKnight (Dallas, TX); Andrew A. Pieper (Iowa City, IA); Joseph M. Ready (Carrollton, TX); Jef K. De Brabander (Flower Mound, TX)
Assignee: Board of Regents of the University of Texas System
C07D209/88A61K31/403A61K31/404A61K31/4045A61K31/4155A61K31/4188A61K31/4192A61K31/422A61K31/437A61K31/4439A61K31/506C07D209/08C07D209/82C07D209/86C07D401/06C07D401/12C07D403/06C07D403/12C07D405/12C07D413/06C07D471/04C07D495/04C07F5/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,820
App. No.
15/250,117
Granted
Feb 6, 2018
Kind
B2
Abstract

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

Claims (39)

1. A compound having formula (III) or a pharmaceutically acceptable salt thereof:

wherein:

each of R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , and R 8 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , cyano, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), and nitro;

R 3 is selected from halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , cyano, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), and nitro;

each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c ;

A is CR A1 R A2 , wherein one of R A1 and R A2 is halo, and the other of R A1 and R A2 is hydrogen, halo, C 1 -C 3 unsubstituted alkyl, and hydroxyl;

Z is —NR 10 R 11 or —OR 12 or —S(O) n R 13 , wherein n is 0, 1, or 2;

each of R 10 and R 11 is independently selected from:

(a) hydrogen;

(b) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or

(c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 unsubstituted alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;

(d) C 1 -C 6 unsubstituted alkyl or C 1 -C 6 haloalkyl; and

(e) —C(O)(C 1 -C 6 unsubstituted alkyl), —C(O)(C 1 -C 6 haloalkyl), or —C(O)O(C 1 -C 6 unsubstituted alkyl);

wherein one of R 10 and R 11 is (b) or (c) and the other of R 10 and R 11 is (a) or (d) or (e);

each of R 12 and R 13 is:

(i) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or

(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 unsubstituted alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;

R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:

(aa) C 1 -C 6 unsubstituted alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 unsubstituted thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 —[O(CH 2 ) 1-3 ] 1-3 —H; C 1 -C 6 unsubstituted alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 unsubstituted alkyl), —N(C 1 -C 6 unsubstituted alkyl) 2 , —NHC(O)(C 1 -C 6 unsubstituted alkyl);

(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); —C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ; wherein the alkyl portion of each of the foregoing, where applicable, is unsubstituted;

(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 unsubstituted alkyl), NC(O)(C 1 -C 6 unsubstituted alkyl), O, and S; and

(dd) phenyl or heteroaryl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 unsubstituted alkyl), O, and S; wherein each of said phenyl and heteroaryl is optionally substituted with from 1-3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 unsubstituted alkyl), —N(C 1 -C 6 unsubstituted alkyl) 2 , —NHC(O)(C 1 -C 6 unsubstituted alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 unsubstituted alkyl, and C 1 -C 6 haloalkyl;

R c at each occurrence is, independently selected from halo, C 1 -C 6 unsubstituted alkoxy, C 1 -C 6 unsubstituted thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 unsubstituted alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 unsubstituted alkyl), —N(C 1 -C 6 unsubstituted alkyl) 2 , —NHC(O)(C 1 -C 6 unsubstituted alkyl), and cyano; and

R d at each occurrence is, independently selected from hydroxyl, C 1 -C 6 unsubstituted alkoxy, C 1 -C 6 unsubstituted thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 unsubstituted alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 unsubstituted alkyl), N(C 1 -C 6 unsubstituted alkyl) 2 , —NHC(O)(C 1 -C 6 unsubstituted alkyl), and cyano.

2. The compound or salt of claim 1 , wherein R 3 is halo.

3. The compound or salt of claim 2 , wherein R 3 is bromo.

4. The compound or salt of claim 3 , wherein each of R 1 , R 2 , and R 4 is hydrogen.

5. The compound or salt of claim 4 , wherein R 6 is selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano.

6. The compound or salt of claim 4 , wherein R 6 is halo or C 1 -C 6 alkyl.

7. The compound or salt of claim 4 , wherein R 6 is halo.

8. The compound or salt of claim 4 , wherein R 6 is bromo.

9. The compound or salt of claim 8 , wherein each of R 5 , R 7 , and R 8 is hydrogen.

10. The compound or salt of claim 4 , wherein Z is —NR 10 R 11 .

11. The compound or salt of claim 10 , wherein one of R 10 and R 11 is:

(b) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or

(c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 unsubstituted alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;

and the other of R 10 and R 11 is hydrogen.

12. The compound or salt of claim 4 , wherein Z is —OR 12 .

13. The compound or salt of claim 12 , wherein R 12 is C 6 -C 10 aryl that is optionally substituted with from 1-4 R b .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2017
From: MCKNIGHT, STEVEN L; PIEPER, ANDREW A; READY, JOSEPH M; DE BRABANDER, JEF K
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 044163/0035 →
Continuity (6)
Continuation 14790313 · Jul 2, 2015
Division 13177981 · Jul 7, 2011
Continuation In Part 12832056 · Jul 7, 2010
Continuation In Part 12685652 · Jan 11, 2010
Provisional Application 61143755 · Jan 9, 2009
Related Publication 20160362373A1 · Dec 15, 2016